Scientist reported last week (May 9) in Nature Metabolism that 1,5-AG, a monosaccharide utilized as a blood biomarker for human diabetes mellitus due to the fact that levels of the sugar are substantially lower in individuals with diabetes, binds to the spike protein of SARS-CoV-2 and prevents the infection from fusing with human cells– the essential very first action in cell entry. Due to the fact that of the transporters affinity with glucose, 1,5-AG reabsorption can be “competitively hindered by glucose,” he writes, which is high in the urine of people with diabetes. Supplementing the sera from diabetic donors with 1,5-AG lowered the quantity of viral RNA produced in that time. The results recommend that administering 1,5-AG to COVID-19 patients with low levels of it, such as those with diabetes, might potentially enhance scientific outcomes. Cheng adds that his group is presently developing 1,5-AG derivatives in the hopes of discovering one that is efficient in people and testing it in medical trials.See “Growing Evidence Ties COVID-19 to Diabetes Risk”
Researchers reported last week (May 9) in Nature Metabolism that 1,5-AG, a monosaccharide used as a blood biomarker for human diabetes mellitus due to the fact that levels of the sugar are significantly lower in individuals with diabetes, binds to the spike protein of SARS-CoV-2 and prevents the virus from fusing with human cells– the important first step in cell entry. Due to the fact that of the transporters affinity with glucose, 1,5-AG reabsorption can be “competitively prevented by glucose,” he writes, which is high in the urine of people with diabetes. The results suggest that administering 1,5-AG to COVID-19 patients with low levels of it, such as those with diabetes, might potentially enhance clinical outcomes.
